INSERM U1065, C3M, Team 4, Inflammation, Cancer, Cancer Stem Cells, Nice, France. Cancer Research UK, London Research Institute, The Francis Crick Institute, London, United Kingdom.
Haematopoeitic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.
Cancer Res. 2016 Apr 15;76(8):2082-6. doi: 10.1158/0008-5472.CAN-15-2063. Epub 2016 Mar 9.
Acute myeloid leukemia (AML) is sustained by a subpopulation of rare leukemia-initiating cells (LIC) detected in the xenograft assay by their capacity to self-renew and to generate non-LICs in vivo The xenotransplantation model captures functional properties of LICs that have clinical prognostic value. However, the long duration of this in vivo assay has hampered its use as a prognostic tool. Here, we show, using an ex vivo coculture system, that intermediate and poor risk AML patient samples at diagnosis have a 5 to 7 times higher frequency of leukemic long-term culture-initiating cells (L-LTC-IC) compared with the good risk group. We defined a fluorescence dilution factor (FDF) parameter that monitors sample proliferation over 1 week and established a strong correlation of this parameter with the L-LTC-IC frequency. A higher FDF was found for poor prognostic AMLs or for samples capable of engrafting NSG mice compared with good risk AMLs or nonengrafters. Importantly, FDF could classify normal karyotype intermediate risk patients into two groups with a significant difference in their overall survival, thus making this nongenetic and non-in vivo approach a new clinically relevant tool for better diagnosis of AML patients. Cancer Res; 76(8); 2082-6. ©2016 AACR.
急性髓系白血病(AML)由在异种移植试验中检测到的稀有白血病起始细胞(LIC)亚群维持,其通过自我更新和在体内产生非 LIC 的能力来检测。该异种移植模型捕获了具有临床预后价值的 LIC 的功能特性。然而,该体内检测的持续时间长,阻碍了其作为预后工具的使用。在这里,我们使用体外共培养系统显示,与低风险组相比,诊断时中等和高风险 AML 患者样本的白血病长期培养起始细胞(L-LTC-IC)频率高 5 至 7 倍。我们定义了一个荧光稀释因子(FDF)参数,该参数可监测样品在 1 周内的增殖情况,并建立了该参数与 L-LTC-IC 频率之间的强相关性。与低风险 AML 或非嵌合体相比,预后不良的 AML 或能够植入 NSG 小鼠的样本的 FDF 更高。重要的是,FDF 可以将核型正常的中等风险患者分为两组,其总生存率存在显著差异,因此,这种非遗传和非体内方法成为更好地诊断 AML 患者的新的临床相关工具。Cancer Res; 76(8); 2082-6. ©2016 AACR.